-
Anderson DE, Tan CW, Chia WN, Young BE, Linster M, Low JH, Tan YJ, Chen MI, Smith GJD, Leo YS, Lye DC, Wang LF, 2020: Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2[J]. Emerg Microbes Infect, 9, 900-902. doi: 10.1080/22221751.2020.1761267
-
Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M, Wei Y, Atwal GS, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA, 2020: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies[J]. Science, 369, 1014-1018. doi: 10.1126/science.abd0831
-
Becerra-Flores M, Cardozo T (2020) SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. Int J Clin Pract 74: e13525
-
Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, Pekosz A, Lau B, Wesolowski A, Katz L, Shan H, Auwaerter PG, Thomas D, Sullivan DJ, Paneth N, Gehrie E, Spitalnik S, Hod EA, Pollack L, Nicholson WT, Pirofski LA, Bailey JA, Tobian AA, 2020: Deployment of convalescent plasma for the prevention and treatment of COVID-19[J]. J Clin Invest, 130, 2757-2765. doi: 10.1172/JCI138745
-
Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng C, Chai X, He R, Li X, Lv Q, Zhu H, Deng W, Xu Y, Wang Y, Qiao L, Tan Y, Song L, Wang G, Du X, Gao N, Liu J, Xiao J, Su XD, Du Z, Feng Y, Qin C, Qin C, Jin R, Xie XS, 2020: Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells[J]. Cell, 182, 73-84.e16. doi: 10.1016/j.cell.2020.05.025
-
Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY, 2020: Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J]. Emerg Microbes Infect, 9, 221-236. doi: 10.1080/22221751.2020.1719902
-
Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, Chen W, 2020: A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2[J]. Science, 369, 650-655. doi: 10.1126/science.abc6952
-
Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ, 2016: Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody[J]. Science, 351, 1339-1342. doi: 10.1126/science.aad5224
-
Daniloski Z, Guo X, Sanjana NE (2020) The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types. bioRxiv 15:2020.06.14.151357
-
Devasenapathy N, Ye Z, Loeb M, Fang F, Najafabadi BT, Xiao Y, Couban R, Begin P, Guyatt G, 2020: Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis[J]. CMAJ, 192, E745-E755. doi: 10.1503/cmaj.200642
-
Dong N, Yang XM, Ye LW, Chen KC, Chan EWC, Yang MS, Chen S, 2020: Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China[J]. bioRxiv, 9, 121-.
-
Fehr AR, Perlman S, 2015: Coronaviruses: an overview of their replication and pathogenesis[J]. Methods Mol Biol, 1282, 1-23.
-
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C, 2020: Rapid development of an inactivated vaccine candidate for SARS-CoV-2[J]. Science, 369, 77-81. doi: 10.1126/science.abc1932
-
Gralinski LE, Menachery VD (2020) Return of the Coronavirus: 2019-nCoV. Viruses 12
-
Guan WD, Mok CK, Chen ZL, Feng LQ, Li ZT, Huang JC, Ke CW, Deng X, Ling Y, Wu SG, Niu XF, Perera RA, Da Xu Y, Zhao J, Zhang LQ, Li YM, Chen RC, Peiris M, Chen L, Zhong NS, 2015: Characteristics of traveler with middle east respiratory syndrome, China, 2015[J]. Emerg Infect Dis, 21, 2278-2280. doi: 10.3201/eid2112.151232
-
Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH 3rd, Kato T, Lee RE, Yount BL, Mascenik TM, Chen G, Olivier KN, Ghio A, Tse LV, Leist SR, Gralinski LE, Schafer A, Dang H, Gilmore R, Nakano S, Sun L, Fulcher ML, Livraghi-Butrico A, Nicely NI, Cameron M, Cameron C, Kelvin DJ, de Silva A, Margolis DM, Markmann A, Bartelt L, Zumwalt R, Martinez FJ, Salvatore SP, Borczuk A, Tata PR, Sontake V, Kimple A, Jaspers I, O'Neal WK, Randell SH, Boucher RC, Baric RS, 2020: SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract[J]. Cell, 182, 429-446. doi: 10.1016/j.cell.2020.05.042
-
Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, Farzan M, Marasco WA, Liddington RC, 2006: Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R[J]. J Biol Chem, 281, 34610-34616. doi: 10.1074/jbc.M603275200
-
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, Ferbas KG, Tobin NH, Aldrovandi GM, Yang OO, 2020: Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19[J]. N Engl J Med, 383, 1085-1087. doi: 10.1056/NEJMc2025179
-
Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackbourne JL, Heinz BA, Foster D, Higgs RE, Balasubramaniam D, Wang L, Bidshahri R, Kraft L, Hwang Y, Žentelis S, Jepson KR, Goya R, Smith MA, Collins DW, Hinshaw SJ, Tycho SA, Pellacani D, Xiang P, Muthuraman K, Sobhanifar S, Piper MH, Triana FJ, Hendle J, Pustilnik A, Adams AC, Berens SJ, Baric RS, Martinez DR, Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli HM, de Vries M, Mohamed A, Dittmann M, Samanovic M, Mulligan MJ, Goldsmith JA, Hsieh CL, Johnson NV, Wrapp D, McLellan JS, Barnhart BC, Graham BS, Mascola JR, Hansen CL, Falconer E (2020) LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv[Preprint]. https://doi.org/10.1101/2020.09.30.318972
-
Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L, 2020: Potent human neutralizing antibodies elicited by SARS-CoV-2 infection[J]. Nature, 584, 115-119. doi: 10.1038/s41586-020-2380-z
-
Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Foley B, Giorgi EE, Bhattacharya T, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI, LaBranche CC, Montefiori DC (2020) Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv. https://doi.org/10.1101/2020.04.29.069054
-
Le Thanh T, Andreadakis Z, Kumar A, Gomez Roman R, Tollefsen S, Saville M, Mayhew S, 2020: The COVID-19 vaccine development landscape[J]. Nat Rev Drug Discov, 19, 305-306. doi: 10.1038/d41573-020-00073-5
-
Liu L, Liu W, Zheng Y, Jiang X, Kou G, Ding J, Wang Q, Huang Q, Ding Y, Ni W, Wu W, Tang S, Tan L, Hu Z, Xu W, Zhang Y, Zhang B, Tang Z, Zhang X, Li H, Rao Z, Jiang H, Ren X, Wang S, Zheng S, 2020: A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients[J]. Microbes Infect, 22, 206-211. doi: 10.1016/j.micinf.2020.05.008
-
Liu LH, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L, Ho DD, 2020: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike[J]. Nature., 584, 450-456. doi: 10.1038/s41586-020-2571-7
-
Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, Sun L, Duan Y, Cai J, Westerdahl D, Liu X, Xu K, Ho KF, Kan H, Fu Q, Lan K, 2020: Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals[J]. Nature, 582, 557-560. doi: 10.1038/s41586-020-2271-3
-
Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL, 2020: Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections[J]. Nat Med, 26, 1200-1204. doi: 10.1038/s41591-020-0965-6
-
Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C, Huang W, Sun S, Sun Y, Zhu L, Chen Q, Wang N, Nie J, Cui Z, Zhu D, Shaw N, Li XF, Li Q, Xie L, Wang Y, Rao Z, Qin CF, Wang X, 2020: Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody[J]. Science, 369, 1505-1509. doi: 10.1126/science.abc5881
-
Mackay IM, Arden KE, 2015: MERS coronavirus: diagnostics, epidemiology and transmission[J]. Virol J, 12, 222-. doi: 10.1186/s12985-015-0439-5
-
Markus H, Hannah KW, Nadine K, Marcel M, Christian D, Pöhlmann S (2020) The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. https://doi.org/10.1101/2020.01.31.929042
-
Okba NMA, Müller MA, Li WT, Wang CY, Haagmans BL, 2020: Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients[J]. Emerg Infect Dis, 26, 1478-1488. doi: 10.3201/eid2607.200841
-
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z, 2020: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV[J]. Nat Commun, 11, 1620-. doi: 10.1038/s41467-020-15562-9
-
Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K, Veesler D, Corti D, 2020: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody[J]. Nature, 583, 290-295. doi: 10.1038/s41586-020-2349-y
-
Poh CM, Carissimo G, Wang B, Amrun SN, Lee CY, Chee RS, Fong SW, Yeo NK, Lee WH, Torres-Ruesta A, Leo YS, Chen MI, Tan SY, Chai LYA, Kalimuddin S, Kheng SSG, Thien SY, Young BE, Lye DC, Hanson BJ, Wang CI, Renia L, Ng LFP, 2020: Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients[J]. Nat Commun, 11, 2806-. doi: 10.1038/s41467-020-16638-2
-
Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov DS, 2006: Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody[J]. J Biol Chem, 281, 15829-15836. doi: 10.1074/jbc.M600697200
-
Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, Gazumyan A, Finkin S, Hagglof T, Oliveira TY, Viant C, Hurley A, Hoffmann HH, Millard KG, Kost RG, Cipolla M, Gordon K, Bianchini F, Chen ST, Ramos V, Patel R, Dizon J, Shimeliovich I, Mendoza P, Hartweger H, Nogueira L, Pack M, Horowitz J, Schmidt F, Weisblum Y, Michailidis E, Ashbrook AW, Waltari E, Pak JE, Huey-Tubman KE, Koranda N, Hoffman PR, West AP Jr, Rice CM, Hatziioannou T, Bjorkman PJ, Bieniasz PD, Caskey M, Nussenzweig MC, 2020: Convergent antibody responses to SARS-CoV-2 in convalescent individuals[J]. Nature, 584, 437-442. doi: 10.1038/s41586-020-2456-9
-
Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song G, Woehl J, Yang L, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren M, Peng L, Ramirez S, Ricketts J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M, Smith DM, Nemazee D, Teijaro JR, Voss JE, Wilson IA, Andrabi R, Briney B, Landais E, Sok D, Jardine JG, Burton DR, 2020: Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model[J]. Science, 369, 956-963. doi: 10.1126/science.abc7520
-
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB, 2020: Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review[J]. JAMA, 323, 1824-1836.
-
Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F, 2020: Structural basis of receptor recognition by SARS-CoV-2[J]. Nature, 581, 221-224. doi: 10.1038/s41586-020-2179-y
-
Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y, Tong Z, Huang W, Liu WJ, Wu G, Zhang B, Wang L, Qi J, Feng H, Wang FS, Wang Q, Gao GF, Yuan Z, Yan J, 2020: A human neutralizing antibody targets the receptor binding site of SARS-CoV-2[J]. Nature, 26, 1422-1427.
-
Tan Y, Liu F, Xu X, Ling Y, Huang W, Zhu Z, Guo M, Lin Y, Fu Z, Liang D, Zhang T, Fan J, Xu M, Lu H, Chen S, 2020: Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection[J]. Front Med, 5, 1-6.
-
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D, 2020: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 181, 281-292. doi: 10.1016/j.cell.2020.02.058
-
Wan JK, Xing SH, Ding LF, Wang YH, Zhu DD, Rong BW, Wang SQ, Chen K, He CX, Yuan SH, Qiu CL, Zhao C, Zhang XY, Wang XX, Lu YN, Xu JQ, Lan F, 2020: Human IgG cell neutralizing monoclonal antibodies block SARS-CoV-2 infection[J]. Cell Rep, 32, 107918-. doi: 10.1016/j.celrep.2020.107918
-
Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus A, van Kuppeveld FJM, Haagmans BL, Grosveld F, Bosch BJ, 2020: A human monoclonal antibody blocking SARS-CoV-2 infection[J]. Nat Commun, 11, 2251-. doi: 10.1038/s41467-020-16256-y
-
Wang HY, Hou X, Wu X, Liang T, Zhang XM, Wang D, Teng F, Da JY, Duan H, Guo SB, Li YZ, Yu X (2020) SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution. ACS Cent Sci. https://doi.org/10.1101/2020.03.26.994756
-
Wang P, Liu L, Nair MS, Yin MT, Luo Y, Wang Q, Yuan T, Mori K, Solis AG, Yamashita M, Purpura LJ, Laracy JC, Yu J, Sodroski J, Huang YX, Ho DD, 2020: SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease[J]. Emerg Microbes Infect, 9, 2091-2093. doi: 10.1080/22221751.2020.1823890
-
World Health Organization (WHO) (2020) Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
-
Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L, Hoffmann M, Pohlmann S, Graham BS, Callewaert N, Schepens B, Saelens X, McLellan JS, 2020a: Structural basis for potent neutralization of betacoronaviruses by single-domain Camelid antibodies[J]. Cell, 181, 1004-1015. doi: 10.1016/j.cell.2020.04.031
-
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS, 2020b: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 367, 1260-1263. doi: 10.1126/science.abb2507
-
Wu YL, Li C, Xia S, Tian X, Kong Y, Wang Z, Gu C, Zhang R, Tu C, Xie Y, Yang Z, Lu L, Jiang S, Ying T (2020) Identification of human single-domain antibodies against SARS-CoV-2. Cell Host Microbe 27: e895
-
Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, Li Z, Li S, Bi Y, Yang Y, Gong Y, Xiao H, Fan Z, Tan S, Wu G, Tan W, Lu X, Fan C, Wang Q, Liu Y, Zhang C, Qi J, Gao GF, Gao F, Liu L, 2020b: A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2[J]. Science, 368, 1274-1278. doi: 10.1126/science.abc2241
-
Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, Hou J, Huang X, Li D, Ma T, Peng J, Gao S, Shao Y, Zhu H, Lau JY, Wang G, Xie C, Jiang L, Huang A, Yang Z, Zhang K, Hou FF, 2020: Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China[J]. Nat Med, 26, 1494-.
-
Yager EJ, 2020: Antibody-dependent enhancement and COVID-19: moving toward acquittal[J]. Clin Immunol, 217, 108496-. doi: 10.1016/j.clim.2020.108496
-
Yao HP, Lu XY, Chen Q, Xu KJ, Chen Y, Cheng LF, Liu FM, Wu ZG, Wu HB, Jin CZ, Zheng M, Wu NP, Jiang C, Li L (2020) Patient-derived mutations impact pathogenicity of SARS-CoV-2. medRxiv[Preprint]. https://doi.org/10.1101/2020.04.14.20060160
-
Ying T, Li H, Lu L, Dimitrov DS, Jiang S, 2015: Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections[J]. Microbes Infect, 17, 142-148. doi: 10.1016/j.micinf.2014.11.008
-
Yuan M, Liu H, Wu NC, Lee CD, Zhu X, Zhao F, Huang D, Yu W, Hua Y, Tien H, Rogers TF, Landais E, Sok D, Jardine JG, Burton DR, Wilson IA, 2020a: Structural basis of a shared antibody response to SARS-CoV-2[J]. Science, 369, 1119-1123. doi: 10.1126/science.abd2321
-
Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, Mok CKP, Wilson IA, 2020b: A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV[J]. Science, 368, 630-633. doi: 10.1126/science.abb7269
-
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA, 2012: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia[J]. N Engl J Med, 367, 1814-1820. doi: 10.1056/NEJMoa1211721
-
Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, Farzan M, Choe H (2020) The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv 2020.06.12.148726
-
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z, 2020: Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019[J]. Clin Infect Dis, 71, 2027-2034. doi: 10.1093/cid/ciaa344
-
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL, 2020: A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 579, 270-273. doi: 10.1038/s41586-020-2012-7
-
Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Martinez DR, Williamson LE, Chen EC, Jones T, Day S, Myers L, Hassan AO, Kafai NM, Winkler ES, Fox JM, Shrihari S, Mueller BK, Meiler J, Chandrashekar A, Mercado NB, Steinhardt JJ, Ren K, Loo YM, Kallewaard NL, McCune BT, Keeler SP, Holtzman MJ, Barouch DH, Gralinski LE, Baric RS, Thackray LB, Diamond MS, Carnahan RH, Crowe JE Jr (2020) Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584: 443–449